The mock submissions described here serve as a basis for dialog within and outside the FDA to address how data are to be submitted, what data should be submitted, and what regulatory decisions are likely to be made with the data submitted.
Many submissions describe the benefits system as variously slow, over-complex, impersonal and bewildering.
They are wrapped by the Kino-Phylo submission API, described later in this paper.
In our original submission we described a mutation in TLR7, Y892A that disrupts AP-4 interaction.
For example, the project management software package Sequencescape that was developed in-house for the production of large-scale data sets captures instructions used by the automatic submission pipelines described previously.
In the original submission, we described a physiological, early replicative aging-associated event in budding yeast: the formation of a singular and durable protein deposit harboring amyloid-like proteins, which is faithfully partitioned to the mother cell during cell division.
A free demo slot was also proposed to several refused paper submissions that described valuable computational methods.
Additional voluntary genomics data submissions as described in the pharmacogenomics guidance (FDA 2005b) are encouraged so that the best practices for handling these data can continue to be developed.
